REG - Diaceutics PLC - Test Signal Launch and Contract Wins

DiaceuticsAnnouncement

09/12/2021 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20211209:nRSI0494Va&default-theme=true

RNS Number : 0494V  Diaceutics PLC  09 December 2021

9 December 2021

 

Diaceutics PLC

("Diaceutics" or "the Company")

 

Launch of Test Signal and multi-year subscription contracts

 

Diaceutics PLC (https://www.diaceutics.com/) , (AIM: DXRX), the diagnostic
commercialisation company, is pleased to announce the launch of its real-time
Test Signal service in the US. Test Signal alerts a pharma customer when a
patient tests positive for a biomarker linked to the profile of therapeutic
linked to the pharmaceutical company.  This information can now be provided
within days of the test result being recorded by laboratories linked to this
new service. Test Signal allows the opportunity for real time identification
of patients eligible for treatment and follow up by the pharmaceutical
company's marketing organisation. This will allow quicker and better support
to biomarker testing, allowing earlier treatment with the most appropriate
drug treatment sooner.

 

Test Signal was previously available as a monthly report. However, with the
additional investment Diaceutics' has made, Test Signal alert is now available
as a real time report further enhancing the DXRX Diaceutics Commercialisation
Platform. This service now adds to the comprehensive suite of modules now
being offered by Diaceutics, on a subscription basis. Work is now nearing
completion for additional modules that will join Test Signal on the DXRX
Commercialisation Platform.

 

Test Signal was trialled prior to launch with key Pharma clients from the
beginning of November 2021 and the Company is delighted to report that it has
already secured six multiyear data subscriptions for the service. This opens
up a new revenue stream for Diaceutics which will be added to as the
Commercialisation Platform matures, underpinning the Company's confidence in
achieving sustained long-term growth.

 

Peter Keeling, CEO and Founder of Diaceutics, commented:

 

"The launch of Test Signal represents another big step on our journey towards
platformisation of our business model and delivery of recurring, high margin
and scalable multi year subscription revenues. The provision of this
sophisticated real time patient testing data has been made possible by our
investments in DXRX. Test Signal supports our Pharma clients and their
physicians by identifying patient cohorts eligible for treatment sooner than
is currently practicable and where treatment can be more effective, a key goal
for all involved in precision medicine. We have been delighted by the swift
adoption of the service by both existing and new pharma customers."

 

Enquiries:

 Diaceutics PLC
 Philip White, Chief Financial Officer                Via Alma PR

 Stifel Nicolaus Europe Limited (Nomad & Broker)      Tel: +44 (0)20 7710 7600
 Ben Maddison, Stewart Wallace, Nick Adams

 Alma PR                                              Tel: +44(0)20 3405 0205
 Caroline Forde, Kieran Breheny, Matthew Young        diaceutics@almapr.co.uk

About Diaceutics

 

At Diaceutics we believe that every patient should have access to the right
treatment at the right time. We provide the world's leading pharmaceutical
companies with an end-to-end solution for the launch of precision medicine
diagnostics enabled by DXRX - The Diagnostic Network®.

 

DXRX is the world's first diagnostic commercialisation platform for precision
medicine, integrating multiple pipelines of real-world diagnostic testing data
from a global network of laboratories.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCUWARRANUURUA